Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read moreHappy New Year!
Happy New Year! Our offices will be closed on Wednesday, January 1, 2025. As another year comes to a close, we want to thank all of our patients, referring physicians, neighbors and
read moreKeep an Eye on Safety When Choosing Holiday Gifts
Air, BB, pellet and paintball guns may be on children’s holiday wish lists, but are they safe? Eye Injuries from Projectile Toys on the Rise Eye injuries from these types of guns
read moreOffices Closed for Labor Day on 9/2/24
All Texas Retina Associates offices will be closed on Monday, September 2, 2024, in observance of Labor Day. We wish everyone a safe and happy holiday weekend!
read moreDr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read moreCan Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read moreRecent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more